Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
about
Role of insulin in the type 2 diabetes therapy: past, present and futureESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryBenefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewCardiovascular outcomes in trials of oral diabetes medications: a systematic reviewPioglitazone for people with impaired glucose tolerance or impaired fasting blood glucosePioglitazone for people with impaired glucose tolerance or impaired fasting blood glucoseMetformin for people with impaired glucose tolerance or impaired fasting blood glucoseLong-term pharmacotherapy for obesity and overweightVariation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study2-Aminoadipic acid is a biomarker for diabetes riskEffect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsStandards of medical care in diabetes--201210-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyCardiovascular safety of anti-diabetic drugsEarly Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsMetabolomics and Type 2 Diabetes: Translating Basic Research into Clinical ApplicationTreatment of prediabetesTherapeutic Use of Metformin in Prediabetes and Diabetes PreventionCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsIndependent and combined effect of diet and exercise in adults with prediabetesAssessment of pancreatic β-cell function: review of methods and clinical applicationsInterventions to preserve beta-cell function in the management and prevention of type 2 diabetesPostpartum screening for diabetes among women with a history of gestational diabetes mellitusPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyRescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouseβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Type 2 diabetes can be prevented with early pharmacological intervention'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic StudiesDirect angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activationDevelopment and Validation of a Risk-Score Model for Type 2 Diabetes: A Cohort Study of a Rural Adult Chinese PopulationFinnish Diabetes Risk Score Is Associated with Impaired Insulin Secretion and Insulin Sensitivity, Drug-Treated Hypertension and Cardiovascular Disease: A Follow-Up Study of the METSIM CohortTreating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbsMetabolite profiles and the risk of developing diabetesStandards of medical care in diabetes--2013Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure.The prevention of type 2 diabetes.Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.
P2860
Q22241148-846E8B42-9D32-4995-B6CA-311B8310E039Q22241786-FE6313B1-CE7E-43B9-8B89-6A947C32CF39Q22242077-FFBD2A02-8C5B-4522-A14A-DF6CC9D9919CQ22253058-942F1906-1DBB-4FEF-9BC6-19FB91BD040FQ24195168-7D3D2338-086C-4B6C-A316-0332AB31553AQ24202245-A18BE323-332A-40CA-8782-33F4C6DA2D0BQ24235225-4794EB91-4EB5-4AA4-A207-BB66983563A6Q24247723-79541AF2-4858-4CF0-BA14-A1EBA6D12944Q24601415-B88DE115-81AD-48AA-AA0C-3F9330977891Q24617890-80F6B421-3AD6-4E58-AEA1-A2E585EF5E4DQ24628988-A9BFD284-0681-4CAA-9661-14BC15AB09A3Q24632533-335C75F7-F2C9-4741-BA45-CB9C5DD427D5Q24633604-4421D5D8-7987-4DC8-85DD-97BA84093985Q26741082-4011D63A-CA1C-47D6-BD2B-55799C0ECE37Q26767164-39795214-3844-4EA9-A419-4259717BA935Q26774386-B9551DD6-109E-4283-BD02-F1775AAB5182Q26783350-FF4A7C78-1149-4F04-8FDA-FCEF307F9CFDQ26822066-34175E6A-AB65-4DAD-8206-5EADF22C5F8CQ26824616-7057204D-76CF-45BE-BF24-1CE9E0CE7EFAQ26828591-697CBB01-75C2-4055-8DD7-6B2AAC0A949EQ26829445-94E3EBAF-21D8-4C69-8A3A-8E2035D94DB3Q26830871-A62BCC1D-707D-4554-9269-94FD60498538Q27004137-489A10BC-90AA-4770-8E7C-9CE7FD9F3B3CQ27024799-A6DB2281-2FB4-4AB0-9483-EA4061B8F396Q27310125-06F4A659-1180-422A-825D-8335C7CD7763Q27692665-374BF676-8579-4A2E-900F-A5CB6A0A6152Q27694430-6A9D67A3-60DA-4746-A1AD-614B774E80D4Q28221639-44D162B4-05AF-4606-B978-F3C44B59A672Q28485173-A3D49B0A-6FF9-454C-B1B7-F1D72E855BB8Q28551276-DF62736D-2908-4D47-9FC6-7ACBE21F8B39Q28553524-30B5469F-32ED-464E-A94E-7CF5EDF93E71Q28687165-2463FB0A-EE81-4A13-A691-47940B108674Q29615359-37808769-DBA7-4F00-B0E0-B39293653DCEQ29620309-36966026-28C8-4E76-9E49-5504B6417E31Q30392979-C28B4DCF-8A93-4BCC-887C-5A651BF1A1FBQ30438373-DC64CE91-6E54-4002-8B94-A033B554198FQ30484253-3F3286B3-E38A-4151-9F9A-7D7CBDB0AFDCQ30489774-5DFB9F3F-D3F7-4B19-AC20-1B001EF091D4Q30533186-1A1237F9-D12E-437F-8440-743CC87026D6Q30597265-92F30F6A-503B-471A-8BAA-006EA37846DB
P2860
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effect of rosiglitazone on the ...... a randomised controlled trial.
@ast
Effect of rosiglitazone on the ...... a randomised controlled trial.
@en
type
label
Effect of rosiglitazone on the ...... a randomised controlled trial.
@ast
Effect of rosiglitazone on the ...... a randomised controlled trial.
@en
prefLabel
Effect of rosiglitazone on the ...... a randomised controlled trial.
@ast
Effect of rosiglitazone on the ...... a randomised controlled trial.
@en
P2093
P921
P1433
P1476
Effect of rosiglitazone on the ...... a randomised controlled trial.
@en
P2093
B Hoogwerf
DREAM (Diabetes REduction Asse ...... edication) Trial Investigators
H C Gerstein
P Sheridan
R R Holman
P304
P356
10.1016/S0140-6736(06)69420-8
P407
P577
2006-09-01T00:00:00Z